No Data
No Data
Announcement of the projected increase in performance for the first half of 2024 of the Xinjiang Baihua Village Pharmaceutical Group Co., Ltd.
Xinjiang Bai Hua Cun Pharma Tech (600721.SH) expects net income to increase by 35.38% to 103.08% in the first half of the year.
On July 10th, Gelunhui reported that Xinjiang Bai Hua Cun Pharma Tech (Stock Code: 600721.SH) expected to achieve a net income of 17.6 to 26.4 million yuan attributable to shareholders of listed companies in the first half of 2024, which is an increase of 4.6 to 13.4 million yuan compared to the same period last year, a year-on-year increase of 35.38% to 103.08%, based on the initial estimates of the company's financial department. The company is expected to achieve a net profit deducted from non-recurring gains and losses attributable to shareholders of listed companies of 16.5 to 24.5 million yuan in the first half of 2024, a year-on-year increase of 34.40% to 99.56% compared to the same period last year.
Xinjiang Bai Hua Cun Pharma Tech (600721.SH): Terminated the issuance of stocks and withdrew the application documents.
Xinjiang Bai Hua Cun Pharma Tech (600721.SH) issued an announcement that the company will hold the eighth board of directors meeting on June 28, 2024...
Shareholder Hua Ling Industry and Trade pledged 79,525,100 shares of Xinjiang Bai Hua Cun Pharma Tech (600721.SH).
Xinjiang Bai Hua Cun Pharma Tech (600721.SH) announced that its controlling shareholder, Hua Ling Gong Mao, has pledged 79,525,100 shares, accounting for 20.83% of the total share capital of the company.
Baihua Pharmaceutical (600721.SH) announced 2023 annual results with net profit of 129.723 million yuan, turning a year-on-year loss into profit
According to the Zhitong Finance App, Baihua Pharmaceutical (600721.SH) disclosed its 2023 annual report. The company achieved operating revenue of 369 million yuan during the reporting period, an increase of 5.54% over the previous year. Net profit attributable to shareholders of listed companies was 129.723 million yuan, and net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 10.729 million yuan, turning losses into profits over the previous year. Basic earnings per share were 0.0342 yuan/share.
Baihua Pharmaceutical (600721.SH): Does not involve AI technology
Gelonghui, March 26 | Baihua Pharmaceutical (600721.SH) said on the interactive platform that the company mainly provides customers with one-stop outsourcing and technological achievement transformation services for the whole process from drug discovery, pharmaceutical chemical component development, clinical trials and registration, without involving AI technology.
No Data